Business, Financials & MSEI/Thinly Traded Share Analysis
Company: Sigachi Laboratories Limited
Incorporated: 21 November 1994
CIN: L24230TG1994PLC018786
ISIN: INE368H01018
Registered Office: Bonthapally, Sangareddy District, Telangana
Exchange: Metropolitan Stock Exchange of India (MSEI)
MSEI Symbol: SIGACHI
Face Value: ₹10
Paid-up Capital: ~₹6.75 Cr
Authorised Capital: ₹12 Cr
The company is an active public company engaged primarily in pharmaceutical products, bulk drugs and drug intermediates. MSEI records Sigachi Laboratories under the symbol SIGACHI, while NSE is shown as “Not Listed.”
1. Company Overview
Sigachi Laboratories Limited is a Hyderabad/Telangana-based pharmaceutical manufacturing company with roots going back to the 1990s.
Its principal business activity has historically been the manufacture of:
- Bulk pharmaceutical drugs
- Drug intermediates
- Pharmaceutical chemicals
- Other pharmaceutical products
The company’s registered manufacturing location is at Bonthapally, Sangareddy District, Telangana, within one of the important pharmaceutical/chemical manufacturing clusters around Hyderabad.
Historical company filings identify pharmaceutical products, bulk drugs and drug intermediates as the principal operating business.
2. What Does Sigachi Laboratories Do?
Pharmaceutical Manufacturing
The core business is pharmaceutical manufacturing, particularly bulk drugs and drug intermediates.
This places the company further upstream in the pharmaceutical value chain compared with a conventional branded-pharma company.
The business model broadly involves manufacturing pharmaceutical molecules/intermediates that can subsequently be used by pharmaceutical companies in formulation and drug manufacturing.
Manufacturing Facility
The company has its principal registered facility at:
Bonthapally, Sangareddy District, Telangana
Historical environmental filings also document pharmaceutical manufacturing activity at the company’s Gaddapotharam/Alinagar facility in the Sangareddy industrial belt.
3. Business Model
A key feature of Sigachi Laboratories is that it is a relatively small pharmaceutical manufacturing company rather than a large branded-pharmaceutical player.
Its revenue historically has come from two broad areas:
| Business | Description |
|---|---|
| Pharmaceutical products | Bulk drugs & drug intermediates |
| Financial income | Interest on loans/ICDs and fixed deposits |
Older annual-return filings show pharmaceutical products as the principal operating activity, while interest income also contributed materially in certain years.
This is important when analysing the company because operating revenue and investment/interest income should be looked at separately.
4. Financial Performance
Available FY2026 financial data compiled from the company’s MSEI filings shows the following trajectory:
Financials
₹ lakh
| Particulars | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | 195 | 374 | 312 | 326 |
| EBITDA | 142 | 242 | 109 | 132 |
| PBT | 173 | 281 | 152 | 181 |
| PAT | 131 | 197 | 119 | 134 |
| EPS | ₹1.79 | ₹2.69 | ₹1.63 | ₹1.83 |
| Operating Margin | 72.8% | 64.7% | 34.9% | 40.8% |
The FY2026 figures indicate a recovery from FY2025, with revenue rising approximately 4%, EBITDA increasing around 21% and PAT increasing around 13%, according to the available financial compilation.
Important: The FY2026 numbers above should be treated as secondary-source compiled figures; MSEI confirms that audited FY2026 results were filed by the company on 5 June 2026.
5. Profitability
One unusual characteristic of Sigachi Laboratories is its historically high operating profitability.
FY2026:
- Revenue: ~₹3.26 Cr
- EBITDA: ~₹1.32 Cr
- EBITDA margin: ~40.8%
- PAT: ~₹1.34 Cr
- EPS: ₹1.83
The margin profile is substantially higher than that of many conventional pharmaceutical manufacturing companies, although the small absolute revenue base means the numbers can fluctuate considerably from year to year.
6. FY2026 vs FY2025
The latest annual data suggests a positive direction:
Revenue: ₹3.12 Cr → ₹3.26 Cr
EBITDA: ₹1.09 Cr → ₹1.32 Cr
PAT: ₹1.19 Cr → ₹1.34 Cr
EPS: ₹1.63 → ₹1.83
Therefore, FY2026 was a year of profit recovery, although revenue remains modest in absolute terms.
7. Q1 FY2027
MSEI records that the company submitted unaudited results for the quarter ended 30 June 2026 on 3 August 2026.
The company continues to maintain quarterly SEBI/LODR disclosures, shareholding filings and corporate-governance reporting through MSEI.
For an investor, the important things to monitor in FY2027 are:
- Pharmaceutical sales growth
- Sustainability of margins
- Contribution from operating business versus interest income
- Cash generation
- Working-capital requirements
- Any expansion of manufacturing capacity
8. Shareholding
The available FY2026 shareholding data indicates approximately:
| Shareholder Category | Holding |
|---|---|
| Promoters | ~36.98% |
| Resident Individuals | ~40.75% |
| NRIs | ~20.22% |
| Others | ~2.05% |
Total equity shares outstanding are approximately 67.53 lakh shares.
The relatively high NRI and individual ownership is notable for such a small company.
9. Current Share Price & Valuation
This is where investors need to be particularly careful.
Sigachi Laboratories is listed on MSEI, not NSE/BSE. MSEI currently shows:
Symbol: SIGACHI
ISIN: INE368H01018
Trading Status: Active
Listing Status: Listed
MSEI’s displayed previous close was ₹15.45 as of 11 September 2026.
However, because there is extremely limited trading activity, the MSEI displayed price should not automatically be treated as a reliable liquidity-adjusted market value.
An unlisted-share market platform reported an indicative price of approximately ₹52/share as of 14 September 2026, with an estimated market capitalisation of around ₹35 Cr. The platform explicitly describes this as an indicative level rather than a live exchange quote.
Indicative Valuation at ₹52
Using approximately 67.53 lakh shares:
₹52 × 67.53 lakh ≈ ₹35.1 Cr equity value
Against FY2026:
- Revenue: ~₹3.26 Cr
- PAT: ~₹1.34 Cr
- EPS: ~₹1.83
- Book value: ~₹60.68/share
At ₹52, the indicative valuation would therefore be approximately:
P/E: ~28x
P/B: ~0.86x
Market Cap/Sales: ~10.8x
The P/E calculation differs from some third-party displays because of rounding and source differences, so investors should calculate valuation using the latest audited share count and financial statements before transacting.
10. Why Is the Company Interesting?
1. Pharmaceutical Manufacturing Exposure
The company operates in the pharmaceutical manufacturing sector, with bulk drugs and intermediates as its core historical business.
2. Strong Margins
FY2026 EBITDA margin was approximately 40.8% according to the available financial compilation.
3. Small Equity Base
With approximately 67.5 lakh shares outstanding, even modest improvements in earnings can have a meaningful impact on EPS.
4. Profit Recovery
FY2026 showed improvement in EBITDA and PAT compared with FY2025.
5. MSEI Listing
Unlike a completely private unlisted company, Sigachi Laboratories already has an MSEI listing and ISIN, although practical liquidity remains very limited.
11. Key Risks
Very Small Revenue Base
Annual revenue of approximately ₹3.26 Cr is extremely small compared with listed Indian pharmaceutical companies.
A small change in one contract or financial-income component can therefore materially change reported earnings.
Limited Liquidity
This is perhaps the biggest consideration for an investor.
The company is not traded on NSE/BSE and MSEI trading liquidity is extremely limited. Therefore, a quoted or dealer-indicative price does not necessarily mean that an investor can immediately buy or sell the desired quantity at that price.
High Dependence on Non-operating Income
Historical filings show that interest on loans/ICDs and fixed deposits has been a meaningful source of income in addition to pharmaceutical operations.
Investors should therefore examine operating profit separately from total profit.
Small-Company Risk
Compared with larger pharmaceutical companies, the company has:
- Smaller scale
- Smaller product portfolio
- Lower bargaining power
- Higher concentration risk
- Potentially greater earnings volatility
Regulatory & Environmental Risk
Pharmaceutical manufacturing involves significant regulatory, environmental and compliance requirements, particularly for bulk drugs and chemical intermediates.
12. What Investors Should Track
For the next 4–6 quarters, the most important indicators are:
1. Operating revenue
Is pharmaceutical revenue growing consistently?
2. EBITDA
Can the company maintain margins above 30–35%?
3. PAT quality
Is profit being generated from pharmaceutical operations rather than primarily from interest income?
4. Cash flow
Does accounting profit convert into operating cash flow?
5. Debt/ICD exposure
Monitor loans, investments and inter-corporate deposits carefully.
6. Capacity utilisation
Higher utilisation could improve operating leverage.
7. Liquidity
For a MSEI/thinly traded security, the ability to actually transact is as important as valuation.
13. Sigachi Laboratories vs Sigachi Industries
This distinction is extremely important.
| Parameter | Sigachi Laboratories | Sigachi Industries |
|---|---|---|
| Company | Sigachi Laboratories Ltd | Sigachi Industries Ltd |
| CIN | L24230TG1994PLC018786 | Different company |
| Core business | Bulk drugs & intermediates | MCC excipients, APIs, nutrition, etc. |
| Location | Telangana | Telangana/Gujarat/Karnataka |
| Exchange | MSEI | NSE/BSE |
| MSEI Symbol | SIGACHI | Different listed security |
| Nature | Small-cap/thinly traded | Mainstream listed company |
Sigachi Industries is the much larger and more widely followed pharmaceutical-excipients company. Its official website describes it as a major manufacturer of microcrystalline cellulose and a diversified business across pharma excipients, APIs, food/nutrition and O&M.
This report is specifically for Sigachi Laboratories Limited.
14. Company Snapshot
| Parameter | Sigachi Laboratories |
|---|---|
| Established | 1994 |
| Sector | Pharmaceuticals |
| Core Business | Bulk Drugs & Drug Intermediates |
| Registered Office | Telangana |
| CIN | L24230TG1994PLC018786 |
| ISIN | INE368H01018 |
| MSEI Symbol | SIGACHI |
| NSE/BSE | No |
| MSEI | Yes |
| FY26 Revenue | ~₹3.26 Cr |
| FY26 EBITDA | ~₹1.32 Cr |
| FY26 PAT | ~₹1.34 Cr |
| FY26 EPS | ~₹1.83 |
| Indicative Share Price | ~₹52* |
| Indicative Market Cap | ~₹35 Cr* |
| Promoter Holding | ~37% |
| Key Opportunity | Pharmaceutical manufacturing + margin recovery |
| Key Risk | Very small scale + low liquidity |
*Indicative secondary-market information, not a live NSE/BSE quote.
UnlistedCart Takeaway
Sigachi Laboratories Limited is a small Telangana-based pharmaceutical manufacturing company with a focus on bulk drugs and drug intermediates.
The company stands out because of its high reported margins, improving FY2026 profitability and very small equity base. FY2026 revenue was approximately ₹3.26 Cr while PAT was around ₹1.34 Cr, giving an EPS of approximately ₹1.83.
However, this is not a conventional NSE/BSE-listed stock. It is listed on MSEI, where practical liquidity is very limited. Consequently, investors should not look only at the headline valuation; the ability to enter and exit at a reasonable price is an equally important consideration.
The key question going forward is whether Sigachi Laboratories can scale its core pharmaceutical operations while maintaining its unusually high margins and converting reported profits into sustainable operating cash flows.
Disclaimer: MSEI/thinly traded and unlisted-share-market prices can differ materially from each other and may not represent executable liquidity. Financial figures sourced from secondary databases should be cross-checked against the company’s latest audited filings before making an investment decision. This report is for informational purposes only and is not investment advice.
For more such unlisted stocks visit UnlistedCart – Unlisted Shares
